Image not available
Chemicals
HBcAg (HBV) (18 – 27)
<p>HBcAg (HBV) (18-27) is a high-purity synthetic peptide representing the HLA-A<em>0201-restricted cytotoxic T lymphocyte (CTL) epitope of Hepatitis B virus core antigen. This 10-amino acid peptide (FLPSDFFPSV) corresponds to residues 18-27 of the HBV core protein and serves as a key immunogenic epitope recognized by CD8⁺ T cells. Manufactured under stringent quality controls with HPLC-verified purity and comprehen…
SupplierGlobal Technology Co., Ltd.www.hqtechtirz.com
Source categories
About this product
Product information from the supplier.
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | HBcAg (HBV) (18 - 27) |
| CAS NO. | / |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C580H78N10O15 |
| Molecular Weight | 1155.33g/mol |
| Purity (RP-HPLC) | ≥ 98.0% |
| Solubility | Soluble in DMSO, PBS (pH 7‑8) |
| Endotoxin | < 1.0 EU/mg |
| Biological Activity | The HLA-A*0201-restricted CTL epitope of hepatitis B virus core antigen (HBcAg) can induce HBV-specific CD8⁺ T cell immune responses, and can be used for HBV immunity research, vaccine development and T cell therapy. |
| Storage Conditions | Store at -20°C or below, protected from light and moisture. After reconstitution, aliquot and store at -20°C |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
HBcAg (HBV) (18-27) functions as a major histocompatibility complex (MHC) class I-restricted epitope that is processed and presented by antigen-presenting cells. After uptake and proteolytic processing, the peptide binds to HLA-A0201 molecules on the cell surface, forming stable MHC-peptide complexes. These complexes are recognized by T cell receptors (TCRs) on CD8⁺ cytotoxic T lymphocytes, leading to T cell activation, proliferation, and effector functions including cytokine production and cytotoxic activity against HBV-infected cells. The peptide's specific sequence (FLPSDFFPSV) contains anchor residues that confer high binding affinity to HLA-A0201, making it an immunodominant epitope in HBV infection and vaccination contexts.
2.PRODUCT INDICATIONS
T Cell Activation Studies: Evaluation of CD8⁺ T cell activation, proliferation, and cytokine production
Vaccine Development: Assessment of vaccine-induced T cell responses and immunogenicity
Immune Monitoring: Detection and quantification of HBV-specific T cells using ELISPOT, MHC tetramer staining, or intracellular cytokine staining
TCR Screening: Identification and validation of T cell receptors specific for HBV epitopes
Therapeutic Vaccine Research: Development and testing of T cell-based immunotherapies for chronic HBV
HBV Immunology Research: Investigation of HBV-specific T cell responses and immune evasion mechanisms
3.CLINICAL EFFICACY OF PRODUCT
Sequence Accuracy: Verified 10-amino acid sequence (FLPSDFFPSV) corresponding to HBV core antigen 18-27
Biological Activity: Validated in T cell activation assays, MHC binding assays, and immune monitoring applications
Research Reproducibility: Consistent performance in functional assays across multiple batches
Quality Documentation: Certificate of Analysis provided with purity, mass spec, and analytical data
Technical Support: Access to application guidance for immunology research and T cell assays
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
More from this supplier
Global Technology Co., Ltd.
